Withdrawal of Immunosuppression in Pediatric Liver Transplant Recipients
Completed · Phase 1
Conditions studied: Liver Transplant, Liver Transplantation
In brief
Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ. Long-term use of these drugs places transplant recipients at higher risk of serious infections and certain types of cancer. The purpose of this study is to determine whether immunosuppressive drugs can be safely withdrawn over a minimum of 9 months from children who received liver transplants at least 4 years ago.
Key facts
- Study ID
- NCT00320606
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 20
- Starts
- 2006-06-05
- Expected to finish
- 2017-03-13
- Last updated by the study team
- 2018-09-20
Who can join
Age: 4 and older, up to 18. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California, San Francisco — San Francisco, California, United States
- Children's Memorial Hospital — Chicago, Illinois, United States
- Columbia University Medical Center — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.